Oncogenic KrasG12D specific non-covalent inhibitor reprograms tumor microenvironment to prevent and reverse early pre-neoplastic pancreatic lesions and in combination with immunotherapy regresses advanced PDAC in a CD8+ T cells dependent manner

Supporters

Support the authors with ResearchCoin

Tip RSC

Preprint Server

Topics

Biology

Biochemistry

Medicine

Cancer Oncology

Immunology

Show all topics

DOI

10.1101/2023.02.15.528757

License

cc-no